CA2439830A1 - Determining the risk of caries in a patient - Google Patents
Determining the risk of caries in a patient Download PDFInfo
- Publication number
- CA2439830A1 CA2439830A1 CA002439830A CA2439830A CA2439830A1 CA 2439830 A1 CA2439830 A1 CA 2439830A1 CA 002439830 A CA002439830 A CA 002439830A CA 2439830 A CA2439830 A CA 2439830A CA 2439830 A1 CA2439830 A1 CA 2439830A1
- Authority
- CA
- Canada
- Prior art keywords
- saliva
- caries
- added
- patient
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000002925 dental caries Diseases 0.000 title claims abstract description 62
- 210000003296 saliva Anatomy 0.000 claims abstract description 66
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000004310 lactic acid Substances 0.000 claims abstract description 20
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 11
- 244000005700 microbiome Species 0.000 claims description 42
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 34
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 19
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 18
- 210000000214 mouth Anatomy 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims 1
- 239000012928 buffer substance Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 28
- 235000000346 sugar Nutrition 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 16
- 229950006238 nadide Drugs 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229940076788 pyruvate Drugs 0.000 description 15
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 13
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 13
- 229920000742 Cotton Polymers 0.000 description 13
- 230000002503 metabolic effect Effects 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000002824 redox indicator Substances 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000008033 biological extinction Effects 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 7
- 239000002250 absorbent Substances 0.000 description 7
- 230000002745 absorbent Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 6
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 6
- 238000010340 saliva test Methods 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000194019 Streptococcus mutans Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000003139 buffering effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-M (S)-lactate Chemical compound C[C@H](O)C([O-])=O JVTAAEKCZFNVCJ-REOHCLBHSA-M 0.000 description 2
- ZYDGCYWJDWIJCS-UHFFFAOYSA-N 1-methoxyphenazine Chemical compound C1=CC=C2N=C3C(OC)=CC=CC3=NC2=C1 ZYDGCYWJDWIJCS-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- SSJZAXOTLCJNLF-UHFFFAOYSA-M 2,3-bis(4-methylphenyl)tetrazol-2-ium-5-carbonitrile;chloride Chemical compound [Cl-].C1=CC(C)=CC=C1N1[N+](C=2C=CC(C)=CC=2)=NC(C#N)=N1 SSJZAXOTLCJNLF-UHFFFAOYSA-M 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 2
- -1 2-cyclohexylamino Chemical group 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010008488 Glycylglycine Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HWYNRVXFYFQSID-UHFFFAOYSA-M benzo[a]phenoxazin-9-ylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C1=CC=C2C(N=C3C=CC(C=C3O3)=[N+](C)C)=C3C=CC2=C1 HWYNRVXFYFQSID-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229940043257 glycylglycine Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- YWARNRIBWGHMIS-UHFFFAOYSA-N 2-[3-[2-(4,5-dimethyl-1,3-thiazol-2-yl)-3-(4-sulfophenyl)-1h-tetrazol-5-yl]phenoxy]acetic acid Chemical compound S1C(C)=C(C)N=C1N1N(C=2C=CC(=CC=2)S(O)(=O)=O)N=C(C=2C=C(OCC(O)=O)C=CC=2)N1 YWARNRIBWGHMIS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- HYRHLJWTFKJITA-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)propanamide Chemical compound NC(=O)C(CO)CO HYRHLJWTFKJITA-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- VDJKJPMLWJWQIH-UHFFFAOYSA-M 5-ethylphenazin-5-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1 VDJKJPMLWJWQIH-UHFFFAOYSA-M 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 239000007996 HEPPS buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000428 Lactate Dehydrogenases Human genes 0.000 description 1
- 108010080864 Lactate Dehydrogenases Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-M ammoniodiacetate Chemical compound [O-]C(=O)C[NH2+]CC([O-])=O NBZBKCUXIYYUSX-UHFFFAOYSA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BZAQMGZYZWMMRU-UHFFFAOYSA-N benzo[a]phenoxazin-9-ylidene(dimethyl)azanium Chemical compound C1=CC=C2C(N=C3C=CC(C=C3O3)=[N+](C)C)=C3C=CC2=C1 BZAQMGZYZWMMRU-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- PQEPCBUBKRUREA-UHFFFAOYSA-N but-3-ynylazanium;chloride Chemical compound Cl.NCCC#C PQEPCBUBKRUREA-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 150000002988 phenazines Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960004267 taurolidine Drugs 0.000 description 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
Abstract
The invention relates to a method for determining the risk of caries in a patient by analysing the lactic acid and/or lactate in the saliva thereof. T he invention also relates to a method for pin-pointing the place of the risk of caries in a patient.
Description
_1_ Ascertaining the patient-related risk of caries The invention relates to a test which is suitable for ascertaining the patient-related risk of caries by determination of lactic acid andlor lactate.
Prior art Caries is an infectious disease. The causative organisms most frequently mentioned include Streptococcus spp. and lactobacilli. Caries-causing micro-organisms have in common, amongst other things, that they take up and ferment sugars, for example sugars from the diet, and excrete acids as metabolic end products.
A distinction must be made, as a matter of principle, between microbial acid release in the saliva and the release of acid in dental plaque, because the carious lesions of teeth are caused a priori by the acid formed by micro-organisms that adhere to tooth surfaces, also referred to hereinafter as plaque. Local acidification of the environment at the tooth surfaces causes the hydroxyapatite to dissolve and consequently is the chemical cause of the formation of caries lesions.
The rapidity with which plaque may be acidified and how strongly acidified it may become depends, inter alia, on the buffering capacity of the saliva, on the buffering capacity of the plaque liquid, on the microbial growth (Coogan, M.M., Motlekar, H.B.
Journal of the Dental Association of South Africa 51, 823-827 (1996)) and on diffusion processes (Dawes, C., Dibdin, G.H. Journal Dental Research 65, 89-94 (1986)) in the plaque.
This complex interplay of physiological, microbiological and chemical factors gives rise to the caries potential in plaque. These factors are present in degrees that differ from one patient to another.
One of the aims of modern dentistry is to assign patients to risk groups.
Early recognition of the risk of caries, before the occurrence of caries lesions, is beneficial.
Prior art Caries is an infectious disease. The causative organisms most frequently mentioned include Streptococcus spp. and lactobacilli. Caries-causing micro-organisms have in common, amongst other things, that they take up and ferment sugars, for example sugars from the diet, and excrete acids as metabolic end products.
A distinction must be made, as a matter of principle, between microbial acid release in the saliva and the release of acid in dental plaque, because the carious lesions of teeth are caused a priori by the acid formed by micro-organisms that adhere to tooth surfaces, also referred to hereinafter as plaque. Local acidification of the environment at the tooth surfaces causes the hydroxyapatite to dissolve and consequently is the chemical cause of the formation of caries lesions.
The rapidity with which plaque may be acidified and how strongly acidified it may become depends, inter alia, on the buffering capacity of the saliva, on the buffering capacity of the plaque liquid, on the microbial growth (Coogan, M.M., Motlekar, H.B.
Journal of the Dental Association of South Africa 51, 823-827 (1996)) and on diffusion processes (Dawes, C., Dibdin, G.H. Journal Dental Research 65, 89-94 (1986)) in the plaque.
This complex interplay of physiological, microbiological and chemical factors gives rise to the caries potential in plaque. These factors are present in degrees that differ from one patient to another.
One of the aims of modern dentistry is to assign patients to risk groups.
Early recognition of the risk of caries, before the occurrence of caries lesions, is beneficial.
It has not been possible for determination of the patient-related risk of caries by means of plaque analysis to become established in practice because, to reach a diagnosis, a large number of individual samples would have to be taken and analysed. Such tests are laborious and too expensive and their management is too complex.
As an alternative to plaque testing, ascertaining the patient-related risk of caries is attempted by testing saliva. It is accordingly presumed that the quantifiable amounts of Streptococcus mutans and/or lactobacilli in the saliva correlate with the amounts of Streptococcus mutans and/or lactobacilli in the plaque and that it is possible, as a result, to deduce the risk of caries to a patient using a saliva test.
Various methods are available for the determination of caries-causing micro organisms, for example Streptococcus mutans and/or lactobacilli, in saliva.
1. The determination of caries-causing micro-organisms is usually carried out after incubation of the samples for several days in suitable culture media, because the number of micro-organisms originally present is not sufficient to obtain a result directly. After multiplication of the micro-organisms over a period lasting from hours to days, the colony-forming units (CFU's) are counted and the number of micro-organisms present in the sample is deduced (Kneist, S.; Klein, C.; Rupf, S.;
Eschrich, K. Quintessenz (1999) 50, 33-43).
It is disadvantageous that the correlation between the number of carious micro-organisms in the saliva and the risk of caries is no more than unsatisfactory, because it is not the number of micro-organisms but rather their metabolic activity that is crucial. Moreover, incubation of the samples results in the establishment of a culture of pathogenic micro-organisms, which has to be treated with the appropriate cautionary measures in order to minimise risks in the practice.
Special disposal is necessary. In addition to those disadvantages, the incubation methods required to reach a microbiological diagnosis are expensive and very time-consuming.
2. Immunological methods are a further approach to the determination of caries causing micro-organisms in saliva. In this case, monoclonal or polyclonal antibodies against surface structures of the micro-organisms being determined are employed.
Compared to the incubation methods according to section 1, these immunological methods are more specific, faster and cheaper, but have clear failings in terms of reproducibility (Kneist, S.; Klein, C.; Rupf, S.; Eschrich, K. Quintessenz (1999) 50, 33-43). For example, saliva contains not only viable micro-organisms but also considerable quantities of micro-organisms that have died. The ratio between dead and viable micro-organisms may differ from one patient to another. The fact that the antibodies are unable to distinguish between viable micro-organisms and dead micro-organisms means that there is an unpredictable range of variation when deducing the existing pathogenic potential of the micro-organisms evaluated (Aass, A.M.; Preus, H.R., Zambon, J.J., Gjermo, P. Scand J. Dent Res (1994) 102, 355-360). Furthermore, the reservation that the correlation between the number of carious micro-organisms in the saliva and the risk of caries is no more than unsatisfactory, because it is not the number of micro-organisms but rather their metabolic activity that is crucial, also holds true in this case.
3. The method having the highest sensitivity is based on polymerase chain reaction (PCR) technology. Minute quantities of micro-organisms can be detected with a high degree of specificity. The PCR technology is time-consuming, complex, costly and not easily mastered (Rupf, S., Kneist, S., Merte, K., Eschrich, K.
Eur. J.
Oral. Sci. (1999) 107, 75-81). In this case too, the reservation that a distinction is not made between living and dead micro-organisms must also be made.
Furthermore, the additional reservation that the correlation between the number of carious micro-organisms in the saliva and the risk of caries is no more than unsatisfactory, because it is not the number of micro-organisms but rather their metabolic activity that is crucial, also holds true in this case.
All methods for the quantification of caries-causing micro-organisms in the saliva in order to ascertain the risk of caries have the crucial disadvantage that it is not possible to reach the desired finding - the patient-related risk of caries - because it is not possible to deduce, from the amounts of caries-causing micro-organisms present in the saliva, the caries potential thereof in plaque.
As an alternative to plaque testing, ascertaining the patient-related risk of caries is attempted by testing saliva. It is accordingly presumed that the quantifiable amounts of Streptococcus mutans and/or lactobacilli in the saliva correlate with the amounts of Streptococcus mutans and/or lactobacilli in the plaque and that it is possible, as a result, to deduce the risk of caries to a patient using a saliva test.
Various methods are available for the determination of caries-causing micro organisms, for example Streptococcus mutans and/or lactobacilli, in saliva.
1. The determination of caries-causing micro-organisms is usually carried out after incubation of the samples for several days in suitable culture media, because the number of micro-organisms originally present is not sufficient to obtain a result directly. After multiplication of the micro-organisms over a period lasting from hours to days, the colony-forming units (CFU's) are counted and the number of micro-organisms present in the sample is deduced (Kneist, S.; Klein, C.; Rupf, S.;
Eschrich, K. Quintessenz (1999) 50, 33-43).
It is disadvantageous that the correlation between the number of carious micro-organisms in the saliva and the risk of caries is no more than unsatisfactory, because it is not the number of micro-organisms but rather their metabolic activity that is crucial. Moreover, incubation of the samples results in the establishment of a culture of pathogenic micro-organisms, which has to be treated with the appropriate cautionary measures in order to minimise risks in the practice.
Special disposal is necessary. In addition to those disadvantages, the incubation methods required to reach a microbiological diagnosis are expensive and very time-consuming.
2. Immunological methods are a further approach to the determination of caries causing micro-organisms in saliva. In this case, monoclonal or polyclonal antibodies against surface structures of the micro-organisms being determined are employed.
Compared to the incubation methods according to section 1, these immunological methods are more specific, faster and cheaper, but have clear failings in terms of reproducibility (Kneist, S.; Klein, C.; Rupf, S.; Eschrich, K. Quintessenz (1999) 50, 33-43). For example, saliva contains not only viable micro-organisms but also considerable quantities of micro-organisms that have died. The ratio between dead and viable micro-organisms may differ from one patient to another. The fact that the antibodies are unable to distinguish between viable micro-organisms and dead micro-organisms means that there is an unpredictable range of variation when deducing the existing pathogenic potential of the micro-organisms evaluated (Aass, A.M.; Preus, H.R., Zambon, J.J., Gjermo, P. Scand J. Dent Res (1994) 102, 355-360). Furthermore, the reservation that the correlation between the number of carious micro-organisms in the saliva and the risk of caries is no more than unsatisfactory, because it is not the number of micro-organisms but rather their metabolic activity that is crucial, also holds true in this case.
3. The method having the highest sensitivity is based on polymerase chain reaction (PCR) technology. Minute quantities of micro-organisms can be detected with a high degree of specificity. The PCR technology is time-consuming, complex, costly and not easily mastered (Rupf, S., Kneist, S., Merte, K., Eschrich, K.
Eur. J.
Oral. Sci. (1999) 107, 75-81). In this case too, the reservation that a distinction is not made between living and dead micro-organisms must also be made.
Furthermore, the additional reservation that the correlation between the number of carious micro-organisms in the saliva and the risk of caries is no more than unsatisfactory, because it is not the number of micro-organisms but rather their metabolic activity that is crucial, also holds true in this case.
All methods for the quantification of caries-causing micro-organisms in the saliva in order to ascertain the risk of caries have the crucial disadvantage that it is not possible to reach the desired finding - the patient-related risk of caries - because it is not possible to deduce, from the amounts of caries-causing micro-organisms present in the saliva, the caries potential thereof in plaque.
Because the composition of saliva is different from one patient to another and has an effect on the metabolic capacity of the micro-organisms present (Minah, G.E., McEnery, M.C., Flores, J.A. Archivs Oral Biol. (1986) 31, 633-638), it is recommended that, in addition to the quantification of caries-causing micro-organisms, the acidification of the patient's saliva that can be caused by sugars should also be investigated. The reduction in pH is due to microbial acid release and is seen as a measure of the metabolic activity of the micro-organisms in the saliva. The observed reduction in pH value in the saliva is, however, dependent upon the level of the buffering capacity of a patient's saliva. It is accordingly recommended that, in order to the determine the patient-related risk of caries, the buffering capacity of the saliva should also be combined with the quantification of caries-causing micro-organisms and pH measurement in the saliva .
Clinical experience shows, however, that even the combination of quantification of Streptococcus mutans/lactobacilli, pH determination and buffering capacity cannot provide a reliable finding with respect to the patient-related risk of caries (Kleinfelder and Kirchner "Die diagnostische Sicherheit biologischer Speicheltests zur Bestimmung des individuellen Kariesrisiko" ["The diagnostic reliability of biological saliva tests for determination of the individual risk of caries"], Dtsch. Zahnarztliche Zeitschrift (1993) 48, 646-648).
The specifications US-A-3,332,743 and EP-A-0 097 904 describe a further attempt at deducing the patient-related risk of caries from the metabolic activity of micro-organisms in the saliva. The capacity of saliva to reduce resazurin to resorufin is observed, the metabolic activity of the micro-organisms being said to correlate with the rate of formation of resorufin. The patient-related risk of caries is deduced from the rate at which resorufin is formed. The reduction of resazurin to resorufin is brought about by microbial dehydrogenases. It is not only Streptococcus mutans and lactobacilli which have dehydrogenases that are capable of reducing resazurin to resorufin. For that reason, the resazurin/resorufin test is used in general as a test for the viability of micro-organisms and is accordingly not specific for the caries pathogens which contribute, via acid release, to acidification of the oral environment and it cannot, therefore, be used for ascertaining the patient-related risk of caries.
Clinical experience shows, however, that even the combination of quantification of Streptococcus mutans/lactobacilli, pH determination and buffering capacity cannot provide a reliable finding with respect to the patient-related risk of caries (Kleinfelder and Kirchner "Die diagnostische Sicherheit biologischer Speicheltests zur Bestimmung des individuellen Kariesrisiko" ["The diagnostic reliability of biological saliva tests for determination of the individual risk of caries"], Dtsch. Zahnarztliche Zeitschrift (1993) 48, 646-648).
The specifications US-A-3,332,743 and EP-A-0 097 904 describe a further attempt at deducing the patient-related risk of caries from the metabolic activity of micro-organisms in the saliva. The capacity of saliva to reduce resazurin to resorufin is observed, the metabolic activity of the micro-organisms being said to correlate with the rate of formation of resorufin. The patient-related risk of caries is deduced from the rate at which resorufin is formed. The reduction of resazurin to resorufin is brought about by microbial dehydrogenases. It is not only Streptococcus mutans and lactobacilli which have dehydrogenases that are capable of reducing resazurin to resorufin. For that reason, the resazurin/resorufin test is used in general as a test for the viability of micro-organisms and is accordingly not specific for the caries pathogens which contribute, via acid release, to acidification of the oral environment and it cannot, therefore, be used for ascertaining the patient-related risk of caries.
A further possibility, discussed in the literature, for ascertaining the metabolic activity of caries-causing micro-organisms which damages the hard substance of teeth is the release of acids, for example formic acid, acetic acid, propionic acid and lactic acid.
Which acids are crucially involved in damaging the hard substance of teeth is dependent on, for example, the supply of nutrients. If sufficient glucose is present, streptococci secrete lactic acid preferentially whereas, when the availability of glucose is limited, acetic acid, propionic acid and formic acid are formed preferentially.
The patent specifications US-A-4,351,899 and US-A-4,254,222 describe a method for the enzymatic determination of lactic acid in biological fluids, especially blood. As a result of enzymatic reduction of lactic acid by a dehydrogenase there is formed, besides pyruvate, nicotinamide adenine dinucleotide (NADH). NADH is subsequently determined using redox indicators, preferably tetrazolium derivatives and phenazine derivatives. Transferring this process to saliva would make possible a rapid and simple method for the determination of the metabolic activity of cariogenic micro-organisms and, consequently, of the risk of caries. The process described in those specifications cannot, however, be used in the case of saliva because a subsidiary reaction which occurs in the saliva crucially falsifies the signal generated by the redox indicators. Even without addition of the dehydrogenase required for the detection reaction, the redox indicators are reduced by saliva components in combination with NAD and signals are produced which are not attributable to the presence of lactate in the saliva.
Pro I m The problem of the present invention is accordingly to provide a method which makes possible evaluation of the prevailing patient-related risk of caries and, in the process, avoids the known disadvantages of the prior art.
Solution It has been found, surprisingly, that patients having an increased risk of caries can be identified by the test used in the context of the method according to the invention.
Which acids are crucially involved in damaging the hard substance of teeth is dependent on, for example, the supply of nutrients. If sufficient glucose is present, streptococci secrete lactic acid preferentially whereas, when the availability of glucose is limited, acetic acid, propionic acid and formic acid are formed preferentially.
The patent specifications US-A-4,351,899 and US-A-4,254,222 describe a method for the enzymatic determination of lactic acid in biological fluids, especially blood. As a result of enzymatic reduction of lactic acid by a dehydrogenase there is formed, besides pyruvate, nicotinamide adenine dinucleotide (NADH). NADH is subsequently determined using redox indicators, preferably tetrazolium derivatives and phenazine derivatives. Transferring this process to saliva would make possible a rapid and simple method for the determination of the metabolic activity of cariogenic micro-organisms and, consequently, of the risk of caries. The process described in those specifications cannot, however, be used in the case of saliva because a subsidiary reaction which occurs in the saliva crucially falsifies the signal generated by the redox indicators. Even without addition of the dehydrogenase required for the detection reaction, the redox indicators are reduced by saliva components in combination with NAD and signals are produced which are not attributable to the presence of lactate in the saliva.
Pro I m The problem of the present invention is accordingly to provide a method which makes possible evaluation of the prevailing patient-related risk of caries and, in the process, avoids the known disadvantages of the prior art.
Solution It has been found, surprisingly, that patients having an increased risk of caries can be identified by the test used in the context of the method according to the invention.
The combination of this test with diagnostic dental impressions, for example those according to DE-A-199 26 728, is also in accordance with the invention. By that means it is possible to distinguish between those patients who, despite the fact they show a caries risk in the saliva or on the tongue, do not have plaque on their teeth that carries a risk of caries and those who do have an actual risk.
The advantage of the invention lies, moreover, in the fact that it is possible for the risk of caries in a patient to be clearly ascertained, leading to identification of appropriately directed medication, and for over- and under-treatment to be avoided.
The advantage of the invention lies, furthermore, in the fact that, using the saliva test, it is possible to establish the need for further investigations, for example a diagnostic dental impression, and indeed at the start of treatment, for example in the context of group prophylaxis in schools and kindergartens. It is also advantageous that the course of treatment can be simply monitored.
The expression "risk of caries" is to be understood in the context of the invention as being both the patient's basic risk of suffering from caries and also the risk that is dependent upon the time of day and eating habits. For the purpose of determining the basic risk, which is governed by the fundamental composition of the oral flora, the patient advantageously carries out simple cleaning measures such as, for example, rinsing andlor teeth-cleaning, preferably teeth-cleaning, before the method according to the invention is used. When determining the risk that is dependent upon the time of day and eating habits, the cleaning measure need not be carried out necessarily but in a preferred embodiment of the method according to the invention should nevertheless be performed.
The expressions "comprising" and "containing" in the context of this specification introduce a non-exhaustive listing.
The saliva test used in accordance with the invention is based on the surprising effect that, subject to the meeting of appropriate precautionary conditions, the formation of lactic acid is outstandingly suitable as a measure of the metabolic activity of micro-_7-organisms in the saliva for the determination of the prevailing patient-related risk of caries and can be ascertained by quantification or semi-quantification of the lactic acid.
In the context of the present invention, the expression "lactate" is to be understood as L(+)-lactate, and the expression lactate dehydrogenase (LDH) is to be understood as L(+)-lactate dehydrogenase.
For detection of the lactic acid, it can, in principle, be involved in chemical, biochemical or physical reactions in which detectable signals are generated.
It has been found, surprisingly, that the undesirable subsidiary reaction between redox inhibitors and saliva components can be suppressed by maintaining specific ratios, in terms of amounts, between lactate dehydrogenase, saliva and an inhibitor, namely pyruvate. The reason that this finding is surprising is that pyruvate is a known inhibitor of lactate dehydrogenase (see, for example, Williams, R. A., Andrews, P., Biochem. J.
236, 721-727 (1986); Oba, K., Mura Kami, S., Uritani, I., J. Biochem. 1193-(1977)). For the person skilled in the art it is an unforeseeable solution that, contrary to the technical teaching, the measurement enzyme - in this case lactate dehydrogenase - must be used in the presence of a known inhibitor in order to be able to suppress the unspecific subsidiary reaction of the saliva to an extent such that an enzymatic determination of the lactic acid by means of lactate dehydrogenase and redox inhibitors is possible. The expression pyruvate is to be understood here as being pyruvic acid or its salts, especially its Na or K salt.
For the enzymatic determination of lactic acid in saliva by means of lactate dehydrogenase - which can be obtained, for example, from bacteria, preferably lactobacilli, streptococci or staphylococci, from animals, preferably pigs, bovine animals, chickens or rabbits, from plants, or from human tissue, for example placenta -suitable ratios, in terms of amounts, between the saliva and lactate dehydrogenase must be maintained. Per 0.1 ml of saliva there should be used between 0.001 and 100 units of lactate dehydrogenase, preferably between 0.01 and 10 units of lactate dehydrogenase and very preferably between 0.05 and 1 unit of lactate dehydrogenase.
_8-In addition, pyruvate should be used in concentrations between 0.001 umol and 5 umol per 0.1 ml of saliva, preferably between 0.01 Nmol and 2.5 Nmol per 0.1 ml of saliva and very preferably between 0.01 Nmol and 1 Nmol per 0.1 ml of saliva.
1 unit of lactate dehydrogenase is to be understood as referring to the conversion of 1 Nmol of pyruvate per minute and mg of protein.
By way of example, redox indicators from the following group can be used in accordance with the invention: methylene blue, 5-cyano-2,3-ditolyl-tetrazolium chloride (CTC), 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT), 8-dimethylamino-2,3-benzophenoxazine (Meldola's blue), 1-methoxy-phenazine methosulphate (MPMS) 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulphophenyl)-tetrazolium (MTS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3,3'-(3,3'-dimethoxy-4,4'-biphenylene)-bis[2-(4-nitrophenyl-5-phenyl)]-2H-tetrazolium chloride (NBT), vitro-tetrazolium violet (NTV), phenazine methosulphate (PMS), sodium 3'-[1-[(phenylamino)carbonyl]-3,4-tetrazolium]bis(4-methoxy-6-nitro)-benzenesulphonic acid (XTT), phenazine ethosulphate (PES, WST-1).
Preference is given among those to Meldola's blue, PES, PMS, MTS, MTT and XTT;
special preference is given to PES, PMS, MTS and MTT.
The concentrations of the redox indicators in the test mixture are between 0.001 and mmol/I, preferably between 0.01 and 5 mmol/I, and very preferably between 0.05 and 2 mmol/l.
Depending upon requirements, the redox indicators can be used in the test in solid form, for example in powder, granule or tablet form.
In accordance with the invention, NAD is preferably used in non-limiting, but also in non-inhibiting, amounts, for example in concentrations between 0.01 and 10 mmol/I, preferably between 0.05 and 5 mmol/l, and very preferably between 0.1 and 1 mmol/1, based on the entire test mixture.
-g_ Depending upon requirements, NAD can be used in the test in solid form, for example in powder, granule or tablet form.
Lactate dehydrogenases from bacteria, animals and plants have pH optima between 4.0 and 10Ø Depending upon the lactate dehydrogenase used, suitable buffer solutions having different pH values must be used. Suitable buffer substances are especially members of the following groups:
~ phosphates, for example sodium phosphates, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, pyrophosphate;
~ carbonates, for example sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate;
~ acetic acid/acetate; citric acid/citrate, diethylbarbituric acid, tris(hydroxymethyl)-aminomethane (TRIS), glycine, glycylglycine (Glygly), N-(2-acetamido)-2-amino-ethanesulphonic acid (ACES), N-(2-acetamido)iminodiacetate (ADA), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), N,N-bis(2-hydroxyethyl)glycine (BICINE), 2,2-bis(hydroxyethyl)iminotris(hydroxymethyl)methane (BIS-TRIS), 2-cyclohexylamino)ethanesulphonic acid (CHES), 2-[4-(2-hydroxyethyl-1-piperazine)]ethanesulphonic acid (HEPES), 3-[4-(2-hydroxyethyl-1-piperazinyl)]-propanesulphonic acid (HEPPS), 2-morpholinoethanesulphonic acid (MES), 3-morpholinopropanesulphonic acid (MOPS), piperazine-1,4-bis(2-ethanesulphonic acid) (PIPES), N-[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-tris(hydroxymethyl)-methyl]-glycine (TRICINE).
Special preference is given to phosphate buffers, Tris buffer, Glygly buffer and acetic acidlacetate buffer.
Depending upon the detection reaction, a pH value between 1 and 12 may be required.
The concentrations of the buffer solutions may, depending upon requirements, be between 0.001 mol/I and 5.0 moll, preferably between 0.01 moll and 1.0 moUl, very preferably between 0.1 moll and 0.5 molh.
Adjustment of the pH of the reaction solution can also be achieved by using in the test, depending upon requirements, defined amounts of buffer substances in solid form, for example in powder or tablet form. Should it be necessary, buffer substances may also be used in the test in liquid form.
Buffer substances, redox indicators, NAD and lactate dehydrogenase and other production adjuvants may be added as combinations in solid form or as a combination in solid and liquid form, for example as a powder in a range between 1 mg and 20 g, preferably between 10 mg and 10 g, more preferably between 50 mg and 5 g and very preferably between 100 mg and 1 g, or in tablet form, for example between 1 and 20 tablets, preferably between 2 and 10 tablets, very preferably between 3 and 5 tablets.
The weight of the tablets may be, for example, between 1 mg and 2 g, preferably between 10 mg and 1.5 g, and very preferably between 100 mg and 1 g.
Production adjuvants are to be understood as being, for example, adjuvants that are known from galenical chemistry, for example dextrans, sugars, aluminium oxide, glasses, quartzes, cellulose derivatives, waxes, fats and salts.
Buffer substances, redox indicators, NAD and lactate dehydrogenase can also be added to the saliva sample in liquid form, in which case they can either be added directly if they are liquids or dissolved beforehand in solvents such as water, ethanol or propanol. Volumes of between 0.001 ml and 20 ml, preferably between 0.01 and ml and very preferaby between 0.1 ml and 1 ml, can be used.
The formation of the lactic acid and of the detectable signal can be detected in a continuous process proceeding in parallel, in which case, for example, after a defined time interval of between 0.01 min and 60 min, preferably between 0.1 min and 30 min, very preferably between 1 min and 10 min, the detectable signal is evaluated or the formation of the metabolite to be detected and/or of the detectable signal is terminated.
For the purpose of termination there come into consideration, for example, stopping reagents such as inhibitors, for example phosphate, or a sudden change in pH, for example initiated by hydrochloric acid or sodium hydroxide solution, or the addition of proteases or surfactants.
The formation of the lactic acid can also be carried out in an independent incubation step, in which case, for example after a defined time interval of between 0.01 min and 60 min, preferably between 0.1 min and 30 min, very preferably between 1 min and min, the formation of the lactic acid is terminated.
For the purpose of termination there come into consideration, for example, stopping reagents, as described above, or heating of the sample to temperatures between and 100°C, or a combination of a stopping reagent and temperature increase.
For the purpose of terminating the formation of lactic acid by the micro-organisms, a very great variety of methods may be used, for example ~ irradiation with high-energy light, such as UV
~ radioactive treatment ~ heat treatment ~ pH change, for example by addition of acids or bases ~ addition of surfactants ~ addition of inhibitors, such as heavy metal salts, alkylating agents ~ addition of micro-organism-destroying substances, such as lysozyme, triclosan, chlorhexidine, taurolidine ~ removal of the micro-organisms from the saliva sample being investigated, for example by ultra-filtration, micro-filtration using sterile filters or centrifugation or a suitable combination of two or more of those methods.
For the purpose of carrying out the test according to the invention, for example between 0.001 ml and 20 ml, preferably between 0.01 ml and 10 ml, very preferably between 0.1 ml and 1 ml, of saliva is transferred to a reaction vessel. In general, the amount of saliva used must be at least sufficiently large for a detectable signal to be obtained for the lactate determination as a result of signal-producing additives.
It can also be advantageous to transfer micro-organisms from regions of the oral cavity into the saliva by mechanical action and then to transfer the saliva sample into a reaction vessel. For example, coating on the tongue can be released therefrom using a suitable implement, such as a tongue spatula or scraper, and the sample taken only thereafter.
It is also possible to take, instead of a direct saliva sample, a sample of micro-organisms from a suitable location in the oral cavity by means of suitable sampling devices and to subject that sample, instead of the saliva, to the basic method according to the invention. In this case, preference is given to removal of coating on the tongue from an area of tongue of from 0.01 to 25 cm2, preferably from 0.1 to cm2 and very preferably between 1 and 5 cm2, by means of cotton-wool tips, swabs or other absorbent materials and devices. In general, the tongue coating must be taken from an area of tongue that is at least sufficiently large for a detectable signal to be obtained for the lactate determination as a result of signal-producing additives.
It can be advantageous, for the purpose of standardisation of the detectable signal in the patient-related patient saliva, for substances to be added to the saliva which make possible the maximum possible lactic acid formation, for example sugars, preferably sucrose and glucose. These substances can be introduced either in solid or liquid form or in a combination of solid and liquid form.
It is possible, for example, for the mouth to be rinsed with a sugar solution, such as an aqueous solution of, for example, glucose, fructose, galactose, sucrose and maltose having a content of between 0.1 and 70 % sugar, preferably between 1 and 50 sugar, and very preferably between 5 and 30 % sugar, before sampling of the saliva or removal of the tongue coating.
It can likewise be advantageous for sugars, such as glucose, fructose, galactose, sucrose, maltose, up to saturation between 0.1 and 70 %, preferably 1 and 60 %, and very preferably 10 and 50 % to be added to the saliva sample itself.
It can also be advantageous for between 0.1 and 10 g, preferably between 0.5 and 5 g, and very preferably between 1 and 2 g, of sugar in the form of, for example, a sugar cube, powdered sugar or sugar tablet to be allowed to dissolve in the oral cavity before sampling of the saliva and removal of the tongue coating.
It can be advantageous, for the purpose of removing the tongue coating by means of cotton-wool tips, swabs or other absorbent materials, to soak the latter with a solution containing between 0.1 and 70 % sugar, preferably between 1 and 50 % sugar, and very preferably between 5 and 30 % sugar, and to use them after drying.
In a likewise preferred embodiment of the method according to the invention, the cotton-wool tips, swabs or other absorbent materials used, for example, for removal of the tongue coating can comprise one or more diagnostic constituents such as, for example, sucrose, NAD, MTP, PMS, LDH or pyruvate, as they are described hereinbefore. Preference is given, inter alia, to NAD being present therein.
In an especially preferred embodiment, the cotton-wool tips, swabs or other absorbent materials used, for example, for removal of the tongue coating comprise both at least one sugar solution as described above and at least one diagnostic constituent such as, for example, NAD.
The invention can in practice be made available, for example, in the form of a blister pack, as is described, for example, in DE 297 142 46 U. This mode of presentation allows the methods according to the invention to be carried out in especially simple manner.
The present invention relates also to a method for the location-specific determination of the patient-related risk of caries using a diagnostic impression compound.
In this case, the patient-related risk of caries is first determined by means of the method according to the invention described above and, in the event of a positive risk, an impression is taken of at least one jaw region, for example of the upper and/or lower jaw, using a diagnostic impression compound.
Suitable diagnostic impression compounds are, for example, those from DE-A-199 26 728, especially alginate-, polyether-, silicone- or polyether-silicone-based compounds. Such compounds are hardenable or film-forming carrier materials containing diagnostically useful additives for location- and substance-specific intraoral diagnosis in a preferred amount of from 0.0001 to 10 % by weight. Suitable diagnostic additives are, according to that specification, dye indicators, antibodies, enzymes and any other substance familiar to the skilled person acquainted with the development of diagnostic test systems.
Such impression compounds exhibit, in the fully hardened impression material, a detectable signal - for example a coloration - at those locations where an increased risk of caries is present. For that purpose, metabolites of the caries-promoting micro-organisms are selectively used as the active species in the detection method employed.
In this context it is possible to use, for example, a pre-formulated diagnostic impression compound. It is, however, likewise possible to use a conventional impression compound, which the person carrying out treatment can convert into an impression compound having a diagnostic function by adding diagnostically effective substances.
The invention will be described below in greater detail by means of Examples;
the invention is not to be limited thereby.
Examples A~~plication Exam let~1 For mixing the signal-producing solution, there are transferred to a plastic test tube (2.5 ml) having a screw closure, using a pipette, 0.1 ml of NAD solution (stock solution 30 mmolh NAD in Glygly buffer 50 mmol/I, pH 9.0), 0.1 ml of MTT (stock solution 1.5 mmol/I MTT in Glygly buffer 50 mmol/l, pH 9.0), 0.1 ml of PMS solution (stock solution 1.0 mmol/I PMS in Glygly buffer 50 mmol/I, pH 9.0), 0.1 ml of LDH
solution (stock soluton lactate dehydrogenase (LDH) 60 units/ml in Glygly buffer 50 mmol/I, pH
9.0) and 0.1 ml of pyruvate solution (stock solution pyruvate 25 mmol/l in Glygly buffer 50 mmol/I, pH 9.0), the screw lid is closed and shaking is carried out for 5 sec.
The patient collects saliva from the mouth and transfers at least 1 ml of saliva into a ml plastic test tube having a screw closure. Using a pipette, 0.6 ml is transferred into a reaction vessel already containing 0.25 g of sucrose. The reaction vessel is closed by means of the screw lid and shaken for 5 sec.
After 3 min, the signal-producing solution is added to the saliva sample in the reaction vessel. The closed reaction vessel is shaken for 5 sec. After 3 min, 0.4 ml of acetic acid solution (stock solution acetic acid 1 mol/I in water) is added to the reaction vessel in order to terminate the formation of the detectable signal. The course of the reaction can be followed by the colour change from yellow to blue. Yellow indicates no risk of caries, and the more intense the blue colour, the higher the risk of caries.
At a wavelength of incident light of 570 nm, an extinction DE/min of 0.957 was measured with a UVIKON 930 spectrphotometer using a plastic cell having a volume of 1 ml.
Comaarison Examale 1 a Comparison Example 1a was performed as Application Example 1, but no pyruvate was added. An extinction of 3.3 was measured.
Comparison Examale 1b Comparison Example 1b was performed as Application Example 1, but neither pyruvate nor LDH were added. An extinction of 0.815 was measured.
Comaarison Examale 1c Comparison Example is was performed as Application Example 1, but no LDH was added. An extinction of 0.156 was measured.
The Comparison Examples 1 a to 1 c, together with Application Example 1, show that, even though pyruvate does inhibit the LDH (compare 1 a), the inhibition by pyruvate is over-compensated by increased addition of LDH (compare 1 b) and nevertheless one or more unknown subsidiary reactions are suppressed (compare 1 c).
Application Example 2 For mixing the signal-producing solution, there are transferred to a plastic test tube (2.5 ml) having a screw closure, using a pipette, 0.1 ml of NAD solution (stock solution 3 mmolll NAD in Glygly buffer 50 mmol/l, pH 9.0), 0.1 rnl of MTT (stock solution 0.15 mmol/l MTT in Glygly buffer 50 mmol/l, pH 9.0), 0.1 ml of PMS solution (stock solution 0.1 mmol/I PMS in Glygly buffer 50 mmol/l, pH 9.0), 0.1 ml of LDH
solution (stock soluton lactate dehydrogenase (LDH) 40 units/ml in Glygly buffer 50 mmol/l, pH
9.0), 0.1 ml of pyruvate solution (stock solution pyruvate 2.5 mmol/l in Glygly buffer 50 mmol/l, pH 9.0), the screw lid is closed and shaking is carried out for 5 sec.
Using a pipette, 100 NI are pipetted onto an absorbent swab 2 cm x 0.6 cm x 0.78 mm and freeze-dried. The dried swab is stuck surface-to-surface onto one end of a polyester strip (7 cm x 0.6 cm x 0.25 mm). A saliva sample, as described under Application Example 1, paragraph 2, has been previously prepared in a reaction vessel. The swab on the test strip is introduced into the saliva sample completely.
After 3 min, the test strip swab is immersed in a vessel containing 2 ml of stopping reagent consisting of 50 mmol/I sodium hydrogen phosphate solution having a pH
of 7.5. The greater the intensity of the blue coloration of the swab on the test strip, the higher the risk of caries.
Application Exam Ip a 3 A signal-producing solution is prepared as described in Application Example 2, paragraph 1. The patient allows a sugar cube to dissolve in the mouth and collects saliva from the mouth. A cotton-wool tip (for example, Q-Tip) is introduced into the mouth and left there for 5 sec in order to soak up saliva. The saliva-soaked cotton-wool region of the tip is immersed in the signal-producing solution and left there for 3 min. The blue coloration produced on the cotton-wool region of the cotton-wool tip is then evaluated. The more intense the blue coloration, the higher the risk of caries.
A alic tion Example 4 A test strip is prepared as described in Application Example 2, from paragraph 1. The patient allows a sugar cube to dissolve in the mouth. The test strip is introduced into the mouth and the absorbent swab is placed on the middle of the tongue and rubbed in order to pick up coating from the tongue. The absorbent swab of the test strip is immersed in the signal-producing solution and left there for 3 min. The blue coloration produced on the swab is then evaluated. The more intense the blue coloration, the higher the risk of caries.
Application Example 5 The ingredients, as described in Application Examples 1 to 4, for carrying out the saliva test are contained in this kit. 20 g of alginate (Palgat, from ESPE) are contained in a bag for the diagnostic impression. The alginate is transferred to a mixing bowl (250 ml). A signal-producing solution prepared according to DE-A-199 26 728 and containing 0.26 g of glycylglycine, 0.24 g of tri(hydroxymethyl)aminomethane, 36 mg of NAD, 0.9 mg of phenazine methosulphate, 3 mg of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) and 1850 units of lactate dehydrogenase, by means of which the release of lactic acid by caries-causing micro-organisms in plaque can be observed, is held ready in a vessel. The signal-producing solution is added to the alginate. Without delay, the mixture is mixed with a hand spatula until homogeneous (about 30 sec). Whilst the impression compound is being prepared, the patient allows a sugar cube to dissolve in the mouth. The impression compound is introduced into an impression tray. For taking the impression, the impression tray is pressed against either the upper jaw or the lower jaw and is left there for 3 min. The impression is removed from the mouth. The locations on the teeth that carry metabolically active, caries-causing micro-organisms are shown by blue dots and areas on the impression compound. The more intense the blue coloration, the higher the local risk of caries. The caries risk determined by the saliva test can be compared to the caries risk present on the teeth.
Aaalication Example 6 A blister in accordance with DE 29714246 U is used. A cotton-wool tip (e.g. Q-Tip) is impregnated with a 50 % by weight sugar solution. The cotton-wool tip is introduced into the mouth and rubbed and rotated on the middle of the tongue in order to take up coating from the tongue. The cotton-wool tip is introduced into the first reservoir of the blister. By pressing on the second reservoir, the signal-producing solution, prepared according to Application Example 2, paragraph 1, is passed into the first reservoir. By rotating the cotton-wool tip, the region having the saliva sample is wetted with the signal-producing solution. The cotton-wool tip can be removed from the blister after 3 min.
Coma rison Exam lia a 1 Comparison Examples 1 and 2 were prepared in order to show that the teachings of the patent specifications US 4,351,899 and US 4,254,222 are not suitable for determining the patient-related risk of caries.
In accordance with the teaching of the patent specifications US 4,351,899 and US 4,254,222, 0.1 ml of Glygly buffer solution pH 9.0 containing 0.6 Nmol of lactate, 0.6 pmol of NAD, 0.03 pmol of MTT, 0.02 Nmol of PMS and 0.6 unit of lactate dehydrogenase were added to 100 p1 of saliva and thoroughly mixed. At 570 nm, the course of the reaction was followed using a microplate reader (from Molecular Device).
An increase in extinction of 0.6/min was measured. In the control experiment without saliva, a change in extinction of 1.1/min was measured. Result: saliva inhibits the enzyme lactate dehydrogenase required for signal production by 45 %.
Comparison Examale 2 In accordance with the teaching of the patent specifications US 4,351,899 and US 4,254,222, 0.1 ml of Glygly buffer solution pH 9.0 containing 0.6 umol of lactate, 0.6 Nmol of NAD, 0.03 Nmol of MTT and 0.02 pmol of PMS were added to 100 ~I of saliva and thoroughly mixed. At 570 nm, the course of the reaction was followed using a microplate reader (from Molecular Device). Even without the presence of lactate dehydrogenase, an increase in extinction of 0.4/min was measured. In the comparison experiment in the presence of 0.3 unit of lactate dehydrogenase, a change in extinction of l.2/min was measured. Result: saliva contains components that are themselves able to reduce the redox indicators PMS/MTT and consequently falsify the measurement signal by 50 %.
The advantage of the invention lies, moreover, in the fact that it is possible for the risk of caries in a patient to be clearly ascertained, leading to identification of appropriately directed medication, and for over- and under-treatment to be avoided.
The advantage of the invention lies, furthermore, in the fact that, using the saliva test, it is possible to establish the need for further investigations, for example a diagnostic dental impression, and indeed at the start of treatment, for example in the context of group prophylaxis in schools and kindergartens. It is also advantageous that the course of treatment can be simply monitored.
The expression "risk of caries" is to be understood in the context of the invention as being both the patient's basic risk of suffering from caries and also the risk that is dependent upon the time of day and eating habits. For the purpose of determining the basic risk, which is governed by the fundamental composition of the oral flora, the patient advantageously carries out simple cleaning measures such as, for example, rinsing andlor teeth-cleaning, preferably teeth-cleaning, before the method according to the invention is used. When determining the risk that is dependent upon the time of day and eating habits, the cleaning measure need not be carried out necessarily but in a preferred embodiment of the method according to the invention should nevertheless be performed.
The expressions "comprising" and "containing" in the context of this specification introduce a non-exhaustive listing.
The saliva test used in accordance with the invention is based on the surprising effect that, subject to the meeting of appropriate precautionary conditions, the formation of lactic acid is outstandingly suitable as a measure of the metabolic activity of micro-_7-organisms in the saliva for the determination of the prevailing patient-related risk of caries and can be ascertained by quantification or semi-quantification of the lactic acid.
In the context of the present invention, the expression "lactate" is to be understood as L(+)-lactate, and the expression lactate dehydrogenase (LDH) is to be understood as L(+)-lactate dehydrogenase.
For detection of the lactic acid, it can, in principle, be involved in chemical, biochemical or physical reactions in which detectable signals are generated.
It has been found, surprisingly, that the undesirable subsidiary reaction between redox inhibitors and saliva components can be suppressed by maintaining specific ratios, in terms of amounts, between lactate dehydrogenase, saliva and an inhibitor, namely pyruvate. The reason that this finding is surprising is that pyruvate is a known inhibitor of lactate dehydrogenase (see, for example, Williams, R. A., Andrews, P., Biochem. J.
236, 721-727 (1986); Oba, K., Mura Kami, S., Uritani, I., J. Biochem. 1193-(1977)). For the person skilled in the art it is an unforeseeable solution that, contrary to the technical teaching, the measurement enzyme - in this case lactate dehydrogenase - must be used in the presence of a known inhibitor in order to be able to suppress the unspecific subsidiary reaction of the saliva to an extent such that an enzymatic determination of the lactic acid by means of lactate dehydrogenase and redox inhibitors is possible. The expression pyruvate is to be understood here as being pyruvic acid or its salts, especially its Na or K salt.
For the enzymatic determination of lactic acid in saliva by means of lactate dehydrogenase - which can be obtained, for example, from bacteria, preferably lactobacilli, streptococci or staphylococci, from animals, preferably pigs, bovine animals, chickens or rabbits, from plants, or from human tissue, for example placenta -suitable ratios, in terms of amounts, between the saliva and lactate dehydrogenase must be maintained. Per 0.1 ml of saliva there should be used between 0.001 and 100 units of lactate dehydrogenase, preferably between 0.01 and 10 units of lactate dehydrogenase and very preferably between 0.05 and 1 unit of lactate dehydrogenase.
_8-In addition, pyruvate should be used in concentrations between 0.001 umol and 5 umol per 0.1 ml of saliva, preferably between 0.01 Nmol and 2.5 Nmol per 0.1 ml of saliva and very preferably between 0.01 Nmol and 1 Nmol per 0.1 ml of saliva.
1 unit of lactate dehydrogenase is to be understood as referring to the conversion of 1 Nmol of pyruvate per minute and mg of protein.
By way of example, redox indicators from the following group can be used in accordance with the invention: methylene blue, 5-cyano-2,3-ditolyl-tetrazolium chloride (CTC), 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT), 8-dimethylamino-2,3-benzophenoxazine (Meldola's blue), 1-methoxy-phenazine methosulphate (MPMS) 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulphophenyl)-tetrazolium (MTS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3,3'-(3,3'-dimethoxy-4,4'-biphenylene)-bis[2-(4-nitrophenyl-5-phenyl)]-2H-tetrazolium chloride (NBT), vitro-tetrazolium violet (NTV), phenazine methosulphate (PMS), sodium 3'-[1-[(phenylamino)carbonyl]-3,4-tetrazolium]bis(4-methoxy-6-nitro)-benzenesulphonic acid (XTT), phenazine ethosulphate (PES, WST-1).
Preference is given among those to Meldola's blue, PES, PMS, MTS, MTT and XTT;
special preference is given to PES, PMS, MTS and MTT.
The concentrations of the redox indicators in the test mixture are between 0.001 and mmol/I, preferably between 0.01 and 5 mmol/I, and very preferably between 0.05 and 2 mmol/l.
Depending upon requirements, the redox indicators can be used in the test in solid form, for example in powder, granule or tablet form.
In accordance with the invention, NAD is preferably used in non-limiting, but also in non-inhibiting, amounts, for example in concentrations between 0.01 and 10 mmol/I, preferably between 0.05 and 5 mmol/l, and very preferably between 0.1 and 1 mmol/1, based on the entire test mixture.
-g_ Depending upon requirements, NAD can be used in the test in solid form, for example in powder, granule or tablet form.
Lactate dehydrogenases from bacteria, animals and plants have pH optima between 4.0 and 10Ø Depending upon the lactate dehydrogenase used, suitable buffer solutions having different pH values must be used. Suitable buffer substances are especially members of the following groups:
~ phosphates, for example sodium phosphates, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, pyrophosphate;
~ carbonates, for example sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate;
~ acetic acid/acetate; citric acid/citrate, diethylbarbituric acid, tris(hydroxymethyl)-aminomethane (TRIS), glycine, glycylglycine (Glygly), N-(2-acetamido)-2-amino-ethanesulphonic acid (ACES), N-(2-acetamido)iminodiacetate (ADA), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), N,N-bis(2-hydroxyethyl)glycine (BICINE), 2,2-bis(hydroxyethyl)iminotris(hydroxymethyl)methane (BIS-TRIS), 2-cyclohexylamino)ethanesulphonic acid (CHES), 2-[4-(2-hydroxyethyl-1-piperazine)]ethanesulphonic acid (HEPES), 3-[4-(2-hydroxyethyl-1-piperazinyl)]-propanesulphonic acid (HEPPS), 2-morpholinoethanesulphonic acid (MES), 3-morpholinopropanesulphonic acid (MOPS), piperazine-1,4-bis(2-ethanesulphonic acid) (PIPES), N-[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-tris(hydroxymethyl)-methyl]-glycine (TRICINE).
Special preference is given to phosphate buffers, Tris buffer, Glygly buffer and acetic acidlacetate buffer.
Depending upon the detection reaction, a pH value between 1 and 12 may be required.
The concentrations of the buffer solutions may, depending upon requirements, be between 0.001 mol/I and 5.0 moll, preferably between 0.01 moll and 1.0 moUl, very preferably between 0.1 moll and 0.5 molh.
Adjustment of the pH of the reaction solution can also be achieved by using in the test, depending upon requirements, defined amounts of buffer substances in solid form, for example in powder or tablet form. Should it be necessary, buffer substances may also be used in the test in liquid form.
Buffer substances, redox indicators, NAD and lactate dehydrogenase and other production adjuvants may be added as combinations in solid form or as a combination in solid and liquid form, for example as a powder in a range between 1 mg and 20 g, preferably between 10 mg and 10 g, more preferably between 50 mg and 5 g and very preferably between 100 mg and 1 g, or in tablet form, for example between 1 and 20 tablets, preferably between 2 and 10 tablets, very preferably between 3 and 5 tablets.
The weight of the tablets may be, for example, between 1 mg and 2 g, preferably between 10 mg and 1.5 g, and very preferably between 100 mg and 1 g.
Production adjuvants are to be understood as being, for example, adjuvants that are known from galenical chemistry, for example dextrans, sugars, aluminium oxide, glasses, quartzes, cellulose derivatives, waxes, fats and salts.
Buffer substances, redox indicators, NAD and lactate dehydrogenase can also be added to the saliva sample in liquid form, in which case they can either be added directly if they are liquids or dissolved beforehand in solvents such as water, ethanol or propanol. Volumes of between 0.001 ml and 20 ml, preferably between 0.01 and ml and very preferaby between 0.1 ml and 1 ml, can be used.
The formation of the lactic acid and of the detectable signal can be detected in a continuous process proceeding in parallel, in which case, for example, after a defined time interval of between 0.01 min and 60 min, preferably between 0.1 min and 30 min, very preferably between 1 min and 10 min, the detectable signal is evaluated or the formation of the metabolite to be detected and/or of the detectable signal is terminated.
For the purpose of termination there come into consideration, for example, stopping reagents such as inhibitors, for example phosphate, or a sudden change in pH, for example initiated by hydrochloric acid or sodium hydroxide solution, or the addition of proteases or surfactants.
The formation of the lactic acid can also be carried out in an independent incubation step, in which case, for example after a defined time interval of between 0.01 min and 60 min, preferably between 0.1 min and 30 min, very preferably between 1 min and min, the formation of the lactic acid is terminated.
For the purpose of termination there come into consideration, for example, stopping reagents, as described above, or heating of the sample to temperatures between and 100°C, or a combination of a stopping reagent and temperature increase.
For the purpose of terminating the formation of lactic acid by the micro-organisms, a very great variety of methods may be used, for example ~ irradiation with high-energy light, such as UV
~ radioactive treatment ~ heat treatment ~ pH change, for example by addition of acids or bases ~ addition of surfactants ~ addition of inhibitors, such as heavy metal salts, alkylating agents ~ addition of micro-organism-destroying substances, such as lysozyme, triclosan, chlorhexidine, taurolidine ~ removal of the micro-organisms from the saliva sample being investigated, for example by ultra-filtration, micro-filtration using sterile filters or centrifugation or a suitable combination of two or more of those methods.
For the purpose of carrying out the test according to the invention, for example between 0.001 ml and 20 ml, preferably between 0.01 ml and 10 ml, very preferably between 0.1 ml and 1 ml, of saliva is transferred to a reaction vessel. In general, the amount of saliva used must be at least sufficiently large for a detectable signal to be obtained for the lactate determination as a result of signal-producing additives.
It can also be advantageous to transfer micro-organisms from regions of the oral cavity into the saliva by mechanical action and then to transfer the saliva sample into a reaction vessel. For example, coating on the tongue can be released therefrom using a suitable implement, such as a tongue spatula or scraper, and the sample taken only thereafter.
It is also possible to take, instead of a direct saliva sample, a sample of micro-organisms from a suitable location in the oral cavity by means of suitable sampling devices and to subject that sample, instead of the saliva, to the basic method according to the invention. In this case, preference is given to removal of coating on the tongue from an area of tongue of from 0.01 to 25 cm2, preferably from 0.1 to cm2 and very preferably between 1 and 5 cm2, by means of cotton-wool tips, swabs or other absorbent materials and devices. In general, the tongue coating must be taken from an area of tongue that is at least sufficiently large for a detectable signal to be obtained for the lactate determination as a result of signal-producing additives.
It can be advantageous, for the purpose of standardisation of the detectable signal in the patient-related patient saliva, for substances to be added to the saliva which make possible the maximum possible lactic acid formation, for example sugars, preferably sucrose and glucose. These substances can be introduced either in solid or liquid form or in a combination of solid and liquid form.
It is possible, for example, for the mouth to be rinsed with a sugar solution, such as an aqueous solution of, for example, glucose, fructose, galactose, sucrose and maltose having a content of between 0.1 and 70 % sugar, preferably between 1 and 50 sugar, and very preferably between 5 and 30 % sugar, before sampling of the saliva or removal of the tongue coating.
It can likewise be advantageous for sugars, such as glucose, fructose, galactose, sucrose, maltose, up to saturation between 0.1 and 70 %, preferably 1 and 60 %, and very preferably 10 and 50 % to be added to the saliva sample itself.
It can also be advantageous for between 0.1 and 10 g, preferably between 0.5 and 5 g, and very preferably between 1 and 2 g, of sugar in the form of, for example, a sugar cube, powdered sugar or sugar tablet to be allowed to dissolve in the oral cavity before sampling of the saliva and removal of the tongue coating.
It can be advantageous, for the purpose of removing the tongue coating by means of cotton-wool tips, swabs or other absorbent materials, to soak the latter with a solution containing between 0.1 and 70 % sugar, preferably between 1 and 50 % sugar, and very preferably between 5 and 30 % sugar, and to use them after drying.
In a likewise preferred embodiment of the method according to the invention, the cotton-wool tips, swabs or other absorbent materials used, for example, for removal of the tongue coating can comprise one or more diagnostic constituents such as, for example, sucrose, NAD, MTP, PMS, LDH or pyruvate, as they are described hereinbefore. Preference is given, inter alia, to NAD being present therein.
In an especially preferred embodiment, the cotton-wool tips, swabs or other absorbent materials used, for example, for removal of the tongue coating comprise both at least one sugar solution as described above and at least one diagnostic constituent such as, for example, NAD.
The invention can in practice be made available, for example, in the form of a blister pack, as is described, for example, in DE 297 142 46 U. This mode of presentation allows the methods according to the invention to be carried out in especially simple manner.
The present invention relates also to a method for the location-specific determination of the patient-related risk of caries using a diagnostic impression compound.
In this case, the patient-related risk of caries is first determined by means of the method according to the invention described above and, in the event of a positive risk, an impression is taken of at least one jaw region, for example of the upper and/or lower jaw, using a diagnostic impression compound.
Suitable diagnostic impression compounds are, for example, those from DE-A-199 26 728, especially alginate-, polyether-, silicone- or polyether-silicone-based compounds. Such compounds are hardenable or film-forming carrier materials containing diagnostically useful additives for location- and substance-specific intraoral diagnosis in a preferred amount of from 0.0001 to 10 % by weight. Suitable diagnostic additives are, according to that specification, dye indicators, antibodies, enzymes and any other substance familiar to the skilled person acquainted with the development of diagnostic test systems.
Such impression compounds exhibit, in the fully hardened impression material, a detectable signal - for example a coloration - at those locations where an increased risk of caries is present. For that purpose, metabolites of the caries-promoting micro-organisms are selectively used as the active species in the detection method employed.
In this context it is possible to use, for example, a pre-formulated diagnostic impression compound. It is, however, likewise possible to use a conventional impression compound, which the person carrying out treatment can convert into an impression compound having a diagnostic function by adding diagnostically effective substances.
The invention will be described below in greater detail by means of Examples;
the invention is not to be limited thereby.
Examples A~~plication Exam let~1 For mixing the signal-producing solution, there are transferred to a plastic test tube (2.5 ml) having a screw closure, using a pipette, 0.1 ml of NAD solution (stock solution 30 mmolh NAD in Glygly buffer 50 mmol/I, pH 9.0), 0.1 ml of MTT (stock solution 1.5 mmol/I MTT in Glygly buffer 50 mmol/l, pH 9.0), 0.1 ml of PMS solution (stock solution 1.0 mmol/I PMS in Glygly buffer 50 mmol/I, pH 9.0), 0.1 ml of LDH
solution (stock soluton lactate dehydrogenase (LDH) 60 units/ml in Glygly buffer 50 mmol/I, pH
9.0) and 0.1 ml of pyruvate solution (stock solution pyruvate 25 mmol/l in Glygly buffer 50 mmol/I, pH 9.0), the screw lid is closed and shaking is carried out for 5 sec.
The patient collects saliva from the mouth and transfers at least 1 ml of saliva into a ml plastic test tube having a screw closure. Using a pipette, 0.6 ml is transferred into a reaction vessel already containing 0.25 g of sucrose. The reaction vessel is closed by means of the screw lid and shaken for 5 sec.
After 3 min, the signal-producing solution is added to the saliva sample in the reaction vessel. The closed reaction vessel is shaken for 5 sec. After 3 min, 0.4 ml of acetic acid solution (stock solution acetic acid 1 mol/I in water) is added to the reaction vessel in order to terminate the formation of the detectable signal. The course of the reaction can be followed by the colour change from yellow to blue. Yellow indicates no risk of caries, and the more intense the blue colour, the higher the risk of caries.
At a wavelength of incident light of 570 nm, an extinction DE/min of 0.957 was measured with a UVIKON 930 spectrphotometer using a plastic cell having a volume of 1 ml.
Comaarison Examale 1 a Comparison Example 1a was performed as Application Example 1, but no pyruvate was added. An extinction of 3.3 was measured.
Comparison Examale 1b Comparison Example 1b was performed as Application Example 1, but neither pyruvate nor LDH were added. An extinction of 0.815 was measured.
Comaarison Examale 1c Comparison Example is was performed as Application Example 1, but no LDH was added. An extinction of 0.156 was measured.
The Comparison Examples 1 a to 1 c, together with Application Example 1, show that, even though pyruvate does inhibit the LDH (compare 1 a), the inhibition by pyruvate is over-compensated by increased addition of LDH (compare 1 b) and nevertheless one or more unknown subsidiary reactions are suppressed (compare 1 c).
Application Example 2 For mixing the signal-producing solution, there are transferred to a plastic test tube (2.5 ml) having a screw closure, using a pipette, 0.1 ml of NAD solution (stock solution 3 mmolll NAD in Glygly buffer 50 mmol/l, pH 9.0), 0.1 rnl of MTT (stock solution 0.15 mmol/l MTT in Glygly buffer 50 mmol/l, pH 9.0), 0.1 ml of PMS solution (stock solution 0.1 mmol/I PMS in Glygly buffer 50 mmol/l, pH 9.0), 0.1 ml of LDH
solution (stock soluton lactate dehydrogenase (LDH) 40 units/ml in Glygly buffer 50 mmol/l, pH
9.0), 0.1 ml of pyruvate solution (stock solution pyruvate 2.5 mmol/l in Glygly buffer 50 mmol/l, pH 9.0), the screw lid is closed and shaking is carried out for 5 sec.
Using a pipette, 100 NI are pipetted onto an absorbent swab 2 cm x 0.6 cm x 0.78 mm and freeze-dried. The dried swab is stuck surface-to-surface onto one end of a polyester strip (7 cm x 0.6 cm x 0.25 mm). A saliva sample, as described under Application Example 1, paragraph 2, has been previously prepared in a reaction vessel. The swab on the test strip is introduced into the saliva sample completely.
After 3 min, the test strip swab is immersed in a vessel containing 2 ml of stopping reagent consisting of 50 mmol/I sodium hydrogen phosphate solution having a pH
of 7.5. The greater the intensity of the blue coloration of the swab on the test strip, the higher the risk of caries.
Application Exam Ip a 3 A signal-producing solution is prepared as described in Application Example 2, paragraph 1. The patient allows a sugar cube to dissolve in the mouth and collects saliva from the mouth. A cotton-wool tip (for example, Q-Tip) is introduced into the mouth and left there for 5 sec in order to soak up saliva. The saliva-soaked cotton-wool region of the tip is immersed in the signal-producing solution and left there for 3 min. The blue coloration produced on the cotton-wool region of the cotton-wool tip is then evaluated. The more intense the blue coloration, the higher the risk of caries.
A alic tion Example 4 A test strip is prepared as described in Application Example 2, from paragraph 1. The patient allows a sugar cube to dissolve in the mouth. The test strip is introduced into the mouth and the absorbent swab is placed on the middle of the tongue and rubbed in order to pick up coating from the tongue. The absorbent swab of the test strip is immersed in the signal-producing solution and left there for 3 min. The blue coloration produced on the swab is then evaluated. The more intense the blue coloration, the higher the risk of caries.
Application Example 5 The ingredients, as described in Application Examples 1 to 4, for carrying out the saliva test are contained in this kit. 20 g of alginate (Palgat, from ESPE) are contained in a bag for the diagnostic impression. The alginate is transferred to a mixing bowl (250 ml). A signal-producing solution prepared according to DE-A-199 26 728 and containing 0.26 g of glycylglycine, 0.24 g of tri(hydroxymethyl)aminomethane, 36 mg of NAD, 0.9 mg of phenazine methosulphate, 3 mg of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) and 1850 units of lactate dehydrogenase, by means of which the release of lactic acid by caries-causing micro-organisms in plaque can be observed, is held ready in a vessel. The signal-producing solution is added to the alginate. Without delay, the mixture is mixed with a hand spatula until homogeneous (about 30 sec). Whilst the impression compound is being prepared, the patient allows a sugar cube to dissolve in the mouth. The impression compound is introduced into an impression tray. For taking the impression, the impression tray is pressed against either the upper jaw or the lower jaw and is left there for 3 min. The impression is removed from the mouth. The locations on the teeth that carry metabolically active, caries-causing micro-organisms are shown by blue dots and areas on the impression compound. The more intense the blue coloration, the higher the local risk of caries. The caries risk determined by the saliva test can be compared to the caries risk present on the teeth.
Aaalication Example 6 A blister in accordance with DE 29714246 U is used. A cotton-wool tip (e.g. Q-Tip) is impregnated with a 50 % by weight sugar solution. The cotton-wool tip is introduced into the mouth and rubbed and rotated on the middle of the tongue in order to take up coating from the tongue. The cotton-wool tip is introduced into the first reservoir of the blister. By pressing on the second reservoir, the signal-producing solution, prepared according to Application Example 2, paragraph 1, is passed into the first reservoir. By rotating the cotton-wool tip, the region having the saliva sample is wetted with the signal-producing solution. The cotton-wool tip can be removed from the blister after 3 min.
Coma rison Exam lia a 1 Comparison Examples 1 and 2 were prepared in order to show that the teachings of the patent specifications US 4,351,899 and US 4,254,222 are not suitable for determining the patient-related risk of caries.
In accordance with the teaching of the patent specifications US 4,351,899 and US 4,254,222, 0.1 ml of Glygly buffer solution pH 9.0 containing 0.6 Nmol of lactate, 0.6 pmol of NAD, 0.03 pmol of MTT, 0.02 Nmol of PMS and 0.6 unit of lactate dehydrogenase were added to 100 p1 of saliva and thoroughly mixed. At 570 nm, the course of the reaction was followed using a microplate reader (from Molecular Device).
An increase in extinction of 0.6/min was measured. In the control experiment without saliva, a change in extinction of 1.1/min was measured. Result: saliva inhibits the enzyme lactate dehydrogenase required for signal production by 45 %.
Comparison Examale 2 In accordance with the teaching of the patent specifications US 4,351,899 and US 4,254,222, 0.1 ml of Glygly buffer solution pH 9.0 containing 0.6 umol of lactate, 0.6 Nmol of NAD, 0.03 Nmol of MTT and 0.02 pmol of PMS were added to 100 ~I of saliva and thoroughly mixed. At 570 nm, the course of the reaction was followed using a microplate reader (from Molecular Device). Even without the presence of lactate dehydrogenase, an increase in extinction of 0.4/min was measured. In the comparison experiment in the presence of 0.3 unit of lactate dehydrogenase, a change in extinction of l.2/min was measured. Result: saliva contains components that are themselves able to reduce the redox indicators PMS/MTT and consequently falsify the measurement signal by 50 %.
Claims (9)
1. A method for the determination of the patient-related risk of caries by determination of lactic acid and/or lactate in samples from the oral cavity, wherein, in case of bioliquids having a sample volume of 0.1 ml, between 0.001 and 100 Units of lactate dehydrogenase are added and pyruvate is added in concentrations of between 0.001 µmol and 5 µmol per 0.1 ml of sample volume and, in the case of biofilms which have been obtained from an oral cavity surface of 0.01 to 25 cm2, between 0.001 and 100 Units of lactate dehydrogenase are added, and wherein in both cases NAD is present in a concentration between 0.001 and 10 mmol/l based on the entire test mixture and subsequently the resulting amount of NADH is measured.
2. A method according to claim 1, wherein the sample volume is removed only after transfer of micro-organisms into the saliva by mechanical action on at least one region of the oral cavity.
3. A method according to claim 2, wherein the region of the oral cavity is the tongue.
4. A method according to one of claims 1 to 3, wherein, before carrying out sampling, there is added to the saliva a substance which induces or increases the formation of lactic acid and/or lactate or which impedes or hinders the formation of substances that adversely affect lactic acid and/or lactate.
5. A method according to claim 4, wherein, before carrying out the detection method, at least one buffer solution is added.
6. A method according to one of claims 1 to 5, wherein, after removal of the sample volume from the oral cavity, pyruvate is added to the sample.
7. A method for the location-specific determination of the patient-related risk of caries, wherein a method according to one of the preceding claims is used and subsequently an impression is taken using a diagnostic impression compound comprising a film-forming carrier material and a diagnostic substance.
8. A kit comprising .cndot. at least one sample tube, .cndot. at least one take-up device, .cndot. at least one buffer substance, .cndot. lactate dehydrogenase in an amount to obtain between 0.001 and 100 units per 0.1 ml of sample volume, .cndot. NAD in a concentration between 0.01 and 10 mM, based on the entire test mixture.
9. A kit according to claim 8, additionally comprising .cndot. pyruvate in an amount to obtain concentrations between 0.001 Nmol and µmol per 0.1 ml of sample volume.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10108900A DE10108900B4 (en) | 2001-02-23 | 2001-02-23 | Determination of patient-related caries risk |
DE10108900.7 | 2001-02-23 | ||
PCT/EP2002/001907 WO2002068679A2 (en) | 2001-02-23 | 2002-02-22 | Determining the risk of caries in a patient |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2439830A1 true CA2439830A1 (en) | 2002-09-06 |
Family
ID=7675334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002439830A Abandoned CA2439830A1 (en) | 2001-02-23 | 2002-02-22 | Determining the risk of caries in a patient |
Country Status (9)
Country | Link |
---|---|
US (1) | US7435558B2 (en) |
EP (1) | EP1364045B1 (en) |
JP (1) | JP4417008B2 (en) |
CN (1) | CN1279181C (en) |
AT (1) | ATE408022T1 (en) |
AU (1) | AU2002233357B2 (en) |
CA (1) | CA2439830A1 (en) |
DE (2) | DE10108900B4 (en) |
WO (1) | WO2002068679A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10108900B4 (en) | 2001-02-23 | 2005-03-10 | 3M Espe Ag | Determination of patient-related caries risk |
EP1787627A1 (en) * | 2005-11-17 | 2007-05-23 | 3M Innovative Properties Company | Anti-microbial dental impression material |
DE102005056293A1 (en) * | 2005-11-24 | 2007-05-31 | Wolfgang Arnhold | Early stage detection of dental caries comprises examining and/or analyzing air and/or gaseous micro flora present in the oral cavity on the basis of caries-typical gas portions and/or molecules |
US9833386B2 (en) * | 2006-03-30 | 2017-12-05 | James D. Welch | Method of, and system for smoothing teeth |
DE202006016294U1 (en) | 2006-10-21 | 2008-02-28 | Consolar Solare Energiesysteme Gmbh | Solar collector with combined air heat extraction |
EP2052712A1 (en) * | 2007-10-26 | 2009-04-29 | 3M Innovative Properties Company | Dental composition |
JP5579612B2 (en) * | 2007-10-26 | 2014-08-27 | スリーエム イノベイティブ プロパティズ カンパニー | Dental composition for detecting bacteria, kit of parts thereof and use |
RU2477121C2 (en) | 2007-12-18 | 2013-03-10 | 3М Инновейтив Пропертиз Компани | Dental composition, containing surface-active substance and f-containing compound, method of its manufacturing and application |
MY155568A (en) * | 2008-02-08 | 2015-10-30 | Colgate Palmolive Co | Oral care methods and systems |
JP2011107124A (en) * | 2009-10-22 | 2011-06-02 | Sony Corp | Method for acquiring biological information |
CN102375049A (en) * | 2010-08-04 | 2012-03-14 | 索尼公司 | Biological Information Acquisition Method |
WO2013045443A1 (en) | 2011-09-28 | 2013-04-04 | Emilia Bramanti | Measurement of lactic acid in biological fluids |
ITPI20110104A1 (en) * | 2011-09-28 | 2013-03-29 | Emilia Bramanti | DETERMINATION OF LACTIC ACID IN BIOLOGICAL FLUIDS |
SG11201606034WA (en) | 2014-02-26 | 2016-09-29 | Powder Pharmaceuticals Inc | Device for delivering particles |
US11883132B2 (en) | 2016-10-28 | 2024-01-30 | University Of Washington | System and method for ranking bacterial activity leading to tooth and gum disease |
WO2020100070A1 (en) | 2018-11-13 | 2020-05-22 | 3M Innovative Properties Company | Biochemical dental instrument for detecting caries |
EP4065067A1 (en) | 2019-11-28 | 2022-10-05 | 3M Innovative Properties Company | Oral care composition with cholic acid components for treating caries |
WO2021116873A1 (en) | 2019-12-12 | 2021-06-17 | 3M Innovative Properties Company | Oral care composition with n-acetyl amino acid components for treating caries |
WO2021140437A1 (en) | 2020-01-08 | 2021-07-15 | 3M Innovative Properties Company | Anionic alkyl sulphate component for treating caries |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3332743A (en) | 1963-06-27 | 1967-07-25 | George H Green | Diagnostic test for dental caries activity |
US4324860A (en) | 1978-02-23 | 1982-04-13 | Forsyth Dental Infirmary For Children | Lactate dehydrogenase mutants of Streptococcus mutans |
US4133875A (en) | 1978-02-23 | 1979-01-09 | Forsyth Dental Infirmary For Children | Method of controlling dental caries with streptococcus mutans mutant strains |
US4254222A (en) | 1978-07-19 | 1981-03-03 | Owen Oliver E | Semi-quantitative assay of lactic acid and β-hydroxy butyrate |
US4351899A (en) * | 1978-07-19 | 1982-09-28 | Owen Oliver E | Semi-quantitative assay of metabolic acids |
JPS58225029A (en) | 1982-06-21 | 1983-12-27 | Showa Yakuhin Kako Kk | Simple diagnostic method for tooth decay and device therefor |
US5607672A (en) | 1995-06-07 | 1997-03-04 | University Of Florida Research Foundation, Inc. | Replacement therapy for dental caries |
DE29714246U1 (en) | 1997-08-08 | 1998-12-10 | Thera Ges Fuer Patente | Device for storing and applying a flowable substance |
US6287796B1 (en) | 1998-06-16 | 2001-09-11 | Niadyne Inc | Biochemical method to measure niacin status in a biological sample |
DE19926728B4 (en) | 1999-06-11 | 2011-08-18 | 3M Espe Ag, 82229 | Use of carrier materials and diagnostically useful additives in imaging methods for intraoral diagnostic purposes |
DE10034647C1 (en) * | 2000-07-14 | 2002-04-04 | 3M Espe Ag | Procedure for performing saliva analysis |
DE10108900B4 (en) | 2001-02-23 | 2005-03-10 | 3M Espe Ag | Determination of patient-related caries risk |
-
2001
- 2001-02-23 DE DE10108900A patent/DE10108900B4/en not_active Expired - Fee Related
-
2002
- 2002-02-22 JP JP2002568773A patent/JP4417008B2/en not_active Expired - Fee Related
- 2002-02-22 EP EP02700267A patent/EP1364045B1/en not_active Expired - Lifetime
- 2002-02-22 CN CN02805302.8A patent/CN1279181C/en not_active Expired - Fee Related
- 2002-02-22 AT AT02700267T patent/ATE408022T1/en not_active IP Right Cessation
- 2002-02-22 CA CA002439830A patent/CA2439830A1/en not_active Abandoned
- 2002-02-22 US US10/468,958 patent/US7435558B2/en not_active Expired - Fee Related
- 2002-02-22 DE DE50212760T patent/DE50212760D1/en not_active Expired - Lifetime
- 2002-02-22 AU AU2002233357A patent/AU2002233357B2/en not_active Ceased
- 2002-02-22 WO PCT/EP2002/001907 patent/WO2002068679A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN1646699A (en) | 2005-07-27 |
US20040141960A1 (en) | 2004-07-22 |
CN1279181C (en) | 2006-10-11 |
EP1364045B1 (en) | 2008-09-10 |
EP1364045A2 (en) | 2003-11-26 |
JP4417008B2 (en) | 2010-02-17 |
US7435558B2 (en) | 2008-10-14 |
WO2002068679A3 (en) | 2003-10-02 |
DE10108900B4 (en) | 2005-03-10 |
DE10108900A1 (en) | 2002-09-12 |
ATE408022T1 (en) | 2008-09-15 |
JP2004536574A (en) | 2004-12-09 |
DE50212760D1 (en) | 2008-10-23 |
AU2002233357B2 (en) | 2007-03-01 |
WO2002068679A2 (en) | 2002-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7435558B2 (en) | Ascertaining the patient related risk of caries | |
JP2763635B2 (en) | Detection of diamines in biological fluids | |
US20080166753A1 (en) | Microbial Growth Assay | |
US8034580B2 (en) | Determining presence of antibiotic in a fluid | |
US4976951A (en) | Dental caries diagnostic and localization technique | |
EP1766046B1 (en) | High ph test system for the determination of the presence of an antibiotic in a fluid | |
US20080057531A1 (en) | Systems, kits, and methods for detecting cariogenic bacteria and assessing risk of dental caries | |
CA2065401C (en) | Very rapid detection of fungal infections | |
CA2529278A1 (en) | Improved method for the determination of the presence of an antibiotic in a fluid | |
WO2007052635A1 (en) | Method for rapid detection of oral bacterium | |
JPH0961428A (en) | Method for judging removal of helicobacter pylori based on change rate of pepsinogen i/ii ratio | |
WO2020218052A1 (en) | Periodontopathic bacteria detection method | |
WO1989002926A1 (en) | Process for counting, detecting and identifying mycoplasmas in general and urogenital mycoplasmas in particular and biological medium especially adapted to this purpose | |
CA2713155C (en) | Method for in vitro detection and/or quantification and/or identification of bacteria in a biological material | |
JP4074163B2 (en) | Medium composition for diagnosis of oral infection | |
JPH10148636A (en) | Method for judging elimination of germ of helicobacter pylori based on change rate of pepsinogen i/ii ratio | |
JP2005080574A (en) | Color-developing medium for discriminating candida | |
JP2001204492A (en) | Method for assaying proliferation and activity of microorganism, and method for testing sensitivity | |
JP2000069997A (en) | New method and reagent for measuring lactate dehydrogenase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |